Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 11 new ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ: MDGL) stock declined 4% in pre-market trading Monday after the FDA ...

Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO- ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...